NEJM:Tepotinib treated met exon 14 jump mutation non-small cell lung cancer phase II clinical effect was significant.

In patients with non-small cell lung cancer (NSCLC), 3-4% of patients experienced transcriptional loss of the cancer-causing gene MET 14 exon due to a mutation in the shear site.
evaluated the efficacy and safety of Tepotinib, a highly selective MET inhibitor, in patients with met14 exon jump mutations.
this study was a Phase II clinical study that recruited patients with late stage or metastasis NSCLC mutations of met14 exon jumps to receive 500 mg of Tepotinib treatment once a day for at least 9 months.
the main endpoint of the study was objective response, which analyzed the mutation of met14 exon jumps in patients' body fluids and tissue samples.
as of January 1, 2020, 152 patients had been treated with Tepotinib and 99 had been followed for at least nine months.
independent review showed a 46 per cent response rate for Tepotinib treatment with a medium duration of 11.1 months.
response rate was 48% for 66 patients in the biopsy group and 50% for 60 patients in the tissue biopsy group.
the researchers assessed a treatment response rate of 56%.
28 percent of patients reported level 3 or higher adverse events associated with Tepotinib treatment, and the risk of external edema was 7 percent.
11% of patients stopped taking the drug due to adverse events.
patients observed a therapeutic response at the molecular level through circulating free DNA testing.
study, tepotinib treatment response rate was about 50% for patients with advanced non-small cell lung cancer with met exon 14 jump mutation, and the most common adverse events above level 3 were exostular edema.
.